DIANZANI, Chiara
 Distribuzione geografica
Continente #
NA - Nord America 11.058
EU - Europa 5.896
AS - Asia 3.875
AF - Africa 116
SA - Sud America 106
OC - Oceania 50
Continente sconosciuto - Info sul continente non disponibili 18
Totale 21.119
Nazione #
US - Stati Uniti d'America 10.899
CN - Cina 1.826
IT - Italia 1.823
SG - Singapore 761
IE - Irlanda 743
SE - Svezia 674
FR - Francia 481
DE - Germania 448
FI - Finlandia 330
UA - Ucraina 292
KR - Corea 287
GB - Regno Unito 262
IN - India 216
PL - Polonia 191
VN - Vietnam 187
JP - Giappone 160
AT - Austria 142
CA - Canada 129
TW - Taiwan 101
ID - Indonesia 93
DK - Danimarca 77
BR - Brasile 68
NL - Olanda 68
ES - Italia 62
HK - Hong Kong 59
TR - Turchia 59
BE - Belgio 55
AU - Australia 45
RU - Federazione Russa 43
CH - Svizzera 34
SN - Senegal 30
MX - Messico 29
EG - Egitto 24
PT - Portogallo 23
RO - Romania 23
CZ - Repubblica Ceca 20
IR - Iran 20
ET - Etiopia 19
GR - Grecia 17
EU - Europa 16
AR - Argentina 15
HU - Ungheria 15
HR - Croazia 14
TH - Thailandia 14
UZ - Uzbekistan 14
RS - Serbia 13
MU - Mauritius 10
BG - Bulgaria 9
CL - Cile 9
IL - Israele 9
MY - Malesia 9
NO - Norvegia 9
PH - Filippine 9
SA - Arabia Saudita 9
BY - Bielorussia 8
CO - Colombia 8
DZ - Algeria 8
LB - Libano 8
PK - Pakistan 8
NG - Nigeria 7
ZA - Sudafrica 6
IQ - Iraq 5
NZ - Nuova Zelanda 5
LK - Sri Lanka 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
LT - Lituania 3
MK - Macedonia 3
MO - Macao, regione amministrativa speciale della Cina 3
PE - Perù 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BF - Burkina Faso 2
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
KE - Kenya 2
KZ - Kazakistan 2
LV - Lettonia 2
MA - Marocco 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
BT - Bhutan 1
CY - Cipro 1
EC - Ecuador 1
EE - Estonia 1
JO - Giordania 1
MN - Mongolia 1
QA - Qatar 1
TN - Tunisia 1
TZ - Tanzania 1
UY - Uruguay 1
ZM - Zambia 1
ZW - Zimbabwe 1
Totale 21.119
Città #
Chandler 1.384
Dublin 737
Fairfield 701
Beijing 671
Torino 641
Singapore 610
Santa Clara 589
Ashburn 577
Houston 492
Ann Arbor 397
Dearborn 375
Woodbridge 361
Wilmington 319
Villeurbanne 311
Seattle 289
Jacksonville 278
Princeton 252
Medford 245
Nyköping 236
Cambridge 218
Redwood City 201
Columbus 191
Warsaw 168
Pisa 154
Shanghai 144
Dong Ket 131
Vienna 121
Turin 118
Fremont 97
Milan 96
Nanjing 86
Jakarta 82
Guangzhou 78
Taipei 72
New York 65
Boardman 63
Piemonte 58
Los Angeles 56
Boston 54
Helsinki 50
Chengdu 46
Washington 45
San Diego 42
Hangzhou 41
Toronto 41
Hefei 39
Brussels 35
Munich 34
Tokyo 34
Norwalk 32
Rome 32
Mumbai 31
Wuhan 30
London 29
Falls Church 28
Jinan 27
Kunming 27
Verona 27
Xian 27
Shenyang 26
Chicago 25
Hong Kong 24
Novara 24
Phoenix 24
Zhengzhou 24
Changsha 23
Seoul 22
Düsseldorf 20
Montréal 20
Silver Spring 20
Tianjin 20
Chongqing 19
Hebei 19
Napoli 19
Vercelli 18
Baotou 17
Kharkiv 16
Nanchang 16
Ottawa 15
Pune 15
Istanbul 14
Frankfurt am Main 13
Harbin 13
Philadelphia 13
Bethesda 12
São Paulo 12
Central District 11
Chennai 11
Delhi 11
Groningen 11
Lachine 11
Nürnberg 11
Trieste 11
Amsterdam 10
Belgrade 10
Guiyang 10
Moscow 10
Renton 10
Upper Marlboro 10
Ahmedabad 9
Totale 13.064
Nome #
Role of 4-Hydroxynonenal-Protein Adducts in Human Diseases. 881
Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer 651
Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies 467
A mutation in caspase-9 decreases the expression of BAFFR and ICOS in patients with immunodeficiency and lymphoproliferation 440
Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis 430
Drug delivery nanoparticles in treating chemoresistant tumor cells 397
New chitosan nanospheres for the delivery of 5-fluorouracil: preparation, characterization and in vitro studies. 346
GSH-targeted nanosponges increase doxorubicin-induced toxicity "in vitro" and "in vivo" in cancer cells with high antioxidant defenses 333
Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors 330
ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo 285
Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells 270
Differential induction of IL-17, IL-10, and IL-9 in human T helper cells by B7h and B7.1. 259
Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model 241
Drug Delivery Nanoparticles in Skin Cancers 232
Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression 219
The inclusion complex of 4-hydroxynonenal with a polymeric derivative of Β-cyclodextrin enhances the antitumoralefficacyof the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model 211
Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models. 208
3D advanced human melanoma models 197
Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. 196
Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis 196
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells 184
Solid lipid nanoparticles carrying lipophilic derivatives of doxorubicin: preparation, characterization, and in vitro cytotoxicity studies 182
Development and Characterization of Solid Lipid Nanoparticles Loaded with a Highly Active Doxorubicin Derivative 182
Interaction of aldehydes derived from lipid peroxidation and membrane proteins. 177
AS601245, an anti-inflammatory JNK inhibitor, and clofibrate have a synergistic effect in inducing cell responses and in affecting the gene expression profile, in CaCo-2 colon cancer cells. 176
Mitochondrial Dysfunction in Cancer and Neurodegenerative Diseases: Spotlight on Fatty Acid Oxidation and Lipoperoxidation Products 175
Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies 175
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643 174
α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis 170
Rosiglitazone and AS601245 Decrease Cell Adhesion and Migration through Modulation of Specific Gene Expression in Human Colon Cancer Cells 169
Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance 162
Cyclic nigerosyl-1,6-nigerose-based nanosponges: An innovative pH and time-controlled nanocarrier for improving cancer treatment 157
Low-dose curcuminoid-loaded in dextran nanobubbles can prevent metastatic spreading in prostate cancer cells 156
Antitumor effect of nanosponge-encapsulated camptothecin in human prostate tumors 155
Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. 152
3D advanced melanoma models 152
Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells 148
Analyzing Cysteine Site Neighbors in Proteins to Reveal Dimethyl Fumarate Targets 148
Evaluation of solubility enhancement, antioxidant activity, and cytotoxicity studies of kynurenic acid loaded cyclodextrin nanosponge 145
Antitumor effect of nanosponges-encapsulated camptothecin in human prostate tumors 144
AS601245, an Anti-Inflammatory JNK Inhibitor, Strengthens the Effects of Clofibrate and Affects Gene Expression Profile, in CaCo-2 Colon Cancer Cells 144
Development of Solid Lipid Nanoparticles by Cold Dilution of Microemulsions: Curcumin Loading, Preliminary In Vitro Studies, and Biodistribution 143
Antitumor activity of nanosponge-encapsulated camptothecin in human prostate tumors 135
B7h triggering inhibits adhesiveness and migration of human umbilical vein endothelial cells and tumour cell lines 131
Antitumor activity of nanosponge-encapsulated camptotechin in human prostate tumors. 122
Nanosponge-encapsulated capmtothecin exerted antitumor effect on murine and human prostate cancer cells 120
B7h triggering inhibits the migration of tumor cell lines. 120
Triggering of B7h by the ICOS Modulates Maturation and Migration of Monocyte-Derived Dendritic Cells 119
Effect of Camptothecin nanosponges on anaplastic thyroid cancer models 119
B7h Triggering Inhibits Umbilical Vascular Endothelial Cell Adhesiveness to Colon Carcinoma Cell Lines and Polymorphonuclear Cells. 117
SLN prodotte attraverso la tecnica della coacervazione come veicoli di macromolecole idrofile 115
In Vitro and In Vivo Therapeutic Evaluation of Camptothecin-Encapsulated β-Cyclodextrin Nanosponges in Prostate Cancer 115
Adhesion of polymorphonuclear cells to endothelial cells is physiologically inhibited by Gas6 112
Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion and migration of colon cancer cells 111
Different expression and function of the endocannabinoid system in human epicardial adipose tissue in relation to heart disease 111
Lipid peroxidation-derived aldehydes, 4-hydroxynonenal and malondialdehyde in aging-related disorders 111
DNA damage by lipid peroxidation products: implications in cancer, inflammation and autoimmunity 110
Stearoyl-Chitosan Coated Nanoparticles Obtained by Microemulsion Cold Dilution Technique 109
Latest News on Nanotechnology for Melanoma Therapy and Diagnosis 108
Comparative evaluation of solubility, cytotoxicity and photostability studies of resveratrol and oxyresveratrol loaded nanosponges 107
Endothelial Cell Adhesiveness to Colon Carcinoma Cell Lines and Polymorphonuclear Cells 106
Nanoemulsions as delivery systems for poly-chemotherapy aiming at melanoma treatment 106
Paclitaxel-Loaded Nanosponges Inhibit Growth and Angiogenesis in Melanoma Cell Models 105
Cyclodextrin-Based Nanohydrogels Containing Polyamidoamine Units: A New Dexamethasone Delivery System for Inflammatory Diseases 104
Effects of anti-inflammatory [1, 2, 4]triazolo[4, 3-a] [1, 8]naphthyridine derivatives on human stimulated PMN and endothelial cells: an in vitro study 104
Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases 103
Aldehydic lipid peroxidation products modulate the activity of human neutrophils 102
B7h triggering inhibits umbilical vascular endothelial cell adhesiveness to tumor cell lines and polymorphonuclear cells 101
The application of nanosponges to cancer drug delivery 101
Camptothecin in nanosponges as new therapeutic delivery agent in prostate cancer: in vitro and in vivo evaluation 101
Rosiglitazone, Alone or in Combination with AS601245, an Anti-Inflammatory JNK Inhibitor, Affects Apoptosis, Differentiation and Cell Adhesion in CaCo-2 Human Colon Cancer Cells Through Modulation of Specific Gene Expressions. 101
Aldehydic lipid peroxidation products modulate the attivity of pro-inflammatory cell. 100
Improved Anti-Tumoral Therapeutic Efficacy of 4-Hydroxynonenal Incorporated in Novel Lipid Nanocapsules in 2D and 3D Models 100
Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo 98
A new bevacizumab carrier for intravitreal administration: Focus on stability 96
Cytotoxic effect of Camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in orthotopic xenograft tumors in vivo 95
Improvement in the anti-tumor efficacy of doxorubicin nanosponges in in vitro and in mice bearing breast tumor models 95
Different approaches in SLN formulation for cancer therapy 94
Le nanotecnologie per la salute dei vegetali e dell’uomo 93
Effetto antiadesivo dell’interazione GAS6-endotelio 90
B7h triggering inhibits adhesion of humbilical vascular endothelial cells to colon carcinoma cell lines and polymorphonuclear cells 89
Control of oxidative stress in cancer chemoresistance: spotlight on Nrf2 role 89
Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29) 88
Challangers and Opportunities of Nanoparticle-Based Theranostics in Skin Cancer 88
Carbosilane dendrimers loaded with sirna targeting nrf2 as a tool to overcome cisplatin chemoresistance in bladder cancer cells 88
A preliminary in vitro and in vivo study of the effects of new anthraquinones on neutrophils and bone remodeling 85
Adenosine modulation of primed human neutrophils 85
B7h triggering inhibits the migration of tumor cell lines x 84
PLGA nanoparticles for “inverse vaccination” in Experimental Autoimmune Encephalomyelitis (EAE) 84
GAS6 inhibits granulocyte adhesion to endothelial cells. 82
A preliminary in vitro and in vivo study of the effects of new anthraquinones on neutrophils and bone remodeling. 82
GAS6 inhibits granulocyte adhesion to endothelial cells 82
Improvement in the anti-tumor efficacy of doxorubicin nanosponges in in vitro and in mice bearing breast tumor models 82
Substance P induces COX-2 expression in Human Umbilical Vein Endothelial Cells 81
Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells 81
Triggering of B7h by the inducible costimulator modulates maturation and migration of monocyte-derived dendritic cells 81
Effetto dei surnatanti di colture linfocitarie sulla produzione di anione superossido in granulociti umani 80
Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression 79
Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus 79
Glutathione Bioresponsive Cyclodextrin Nanosponges 79
Totale 16.114
Categoria #
all - tutte 59.630
article - articoli 0
book - libri 0
conference - conferenze 18.236
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.866


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.011 0 0 0 0 0 464 348 282 299 296 151 171
2020/20212.648 250 209 193 200 203 199 208 156 264 231 183 352
2021/20222.570 126 115 101 199 111 103 130 143 137 205 695 505
2022/20233.849 390 328 126 414 320 890 250 283 466 80 177 125
2023/20241.977 199 320 139 145 121 231 94 151 22 147 181 227
2024/20252.202 64 177 191 447 1.040 283 0 0 0 0 0 0
Totale 21.831